Spannerwerks Client BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100

Oct 25

December 21, 2020

Congratulations BioEclipse Therapeutics, Inc on opening enrollment in the Phase 1 study of CRX100! We are proud of the Spannerwerks team that helped open this important oncology study.

Guest User

Spannerwerks Client BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100

Figure design by Spannerwerks' Sara Chumbley in npj Vaccines article on COVID-19 vaccine development acceleration

Best Practices - Building Your Company While Racing to the Clinic